Treatment of Chronic Hepatitis C in a State Correctional Facility
Authors: David Bernstein
Journal: Annals of Internal Medicine (2004)

Letters20 January 2004Treatment of Chronic Hepatitis C in a State Correctional FacilityDavid Bernstein, MDDavid Bernstein, MDFrom North Shore University Hospital, Manhasset, NY 11030.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-2-200401200-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In the past, the treatment of patients with chronic hepatitis C in U.S. correctional facilities has been lacking. Therefore, I commend Allen and colleagues (1) for their recent study on the treatment of 93 individuals with chronic hepatitis C in the Rhode Island Department of Corrections. Despite the authors' excellent intentions, I take issue with some of their statements.The authors state that nearly one third of all Americans with chronic hepatitis C pass through correctional facilities annually. Although the problem of hepatitis C in correctional institutions is daunting, with anywhere from 16% to 41% of inmates ...References1. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-90. [PMID: 12558357] LinkGoogle Scholar2. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey 1988-1994. Vital and Health Statistics. Series 1, no. 32. Washington, DC: U.S. Government Printing Office; July 1994. DHHS publication number 94:1308. Google Scholar3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-92. [PMID: 9819446] CrossrefMedlineGoogle Scholar4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-32. [PMID: 9807989] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: David Bernstein, MDAffiliations: From North Shore University Hospital, Manhasset, NY 11030. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of Chronic Hepatitis C in a State Correctional Facility Scott A. Allen , Anne C. Spaulding , Albert M. Osei , Lynn E. Taylor , Asya M. Cabral , and Josiah D. Rich Treatment of Chronic Hepatitis C in a State Correctional Facility Scott Allen , Anne Spaulding , and Josiah D. Rich Metrics Cited byRecomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciarioRecomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario 20 January 2004Volume 140, Issue 2Page: 150-151KeywordsAdverse eventsChronic hepatitis CFallsHepatitis CInfectious hepatitisIntent to treat analysisPatients ePublished: 20 January 2004 Issue Published: 20 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...